Back
CEPI - Filovirus Vaccines
webCredibility Rating
4/5
High(4)High quality. Established institution or organization with editorial oversight and accountability.
Rating inherited from publication venue: CEPI
This resource covers pandemic preparedness and biosecurity funding, tangentially relevant to AI safety through the lens of existential and catastrophic biological risks and international coordination mechanisms for Disease X scenarios.
Metadata
Importance: 30/100press releasenews
Summary
CEPI is investing up to $18 million to fund Stanford School of Medicine researchers in developing broad-spectrum vaccines that could protect against multiple filoviruses including Zaire Ebolavirus, Marburg, and Sudan Ebolavirus. The project uses AI-designed immunogens combined with a ferritin nanoparticle platform, aiming to create an 'all-in-one' filovirus vaccine and prepare defenses against unknown future filovirus pathogens ('Disease X').
Key Points
- •CEPI is funding up to $18M for Stanford researchers to develop broad-spectrum vaccines against Zaire Ebolavirus, Marburg, Sudan Ebolavirus, and unknown future filoviruses.
- •AI will be used to design immunogens capable of triggering immune responses against multiple filovirus strains simultaneously.
- •The ferritin nanoparticle platform requires no complex cold storage, making it more accessible for low- and middle-income countries.
- •The most promising vaccine candidate will be readied for rapid Phase I clinical trials should an unknown filovirus outbreak occur.
- •Scientific outputs will be added to CEPI's 'Disease X Vaccine Library' to accelerate responses to novel emerging pathogens.
Cited by 1 page
| Page | Type | Quality |
|---|---|---|
| Coalition for Epidemic Preparedness Innovations | Organization | 53.0 |
Cached Content Preview
HTTP 200Fetched Mar 20, 20267 KB
Securing the Future: CEPI 3.0 Investment Case
[Find out more](https://cepi.net/securing-the-future) Dismiss
[Facebook](https://www.facebook.com/sharer/sharer.php?u=https://cepi.net/cepi-backs-new-research-vaccines-against-multiple-deadly-filoviruses) [LinkedIn](https://www.linkedin.com/shareArticle?mini=true&url=https://cepi.net/cepi-backs-new-research-vaccines-against-multiple-deadly-filoviruses) [X](https://twitter.com/intent/tweet?url=https://cepi.net/cepi-backs-new-research-vaccines-against-multiple-deadly-filoviruses)
- **Researchers will test new vaccines that could provide all-in-one protection against viruses including Zaire Ebolavirus, Marburg and Sudan Ebolavirus.**
- **Project will help scientists to rapidly respond if an unknown filovirus pathogen emerges in the future.**
**6 October 2025, OSLO.** CEPI will fund new research conducted by scientists at the Stanford School of Medicine to study whether new vaccines could offer broad protection against multiple deadly pathogens from the filovirus viral family.
Supported by up to $18 million in CEPI investment, researchers will design and test new vaccine constructs that could provide all-in-one protection against viruses including Zaire Ebolavirus, Marburg and Sudan Ebolavirus, and even filoviruses that we don’t yet know about that could spill over from animals into humans in the future.
“A broadly protective filovirus vaccine could transform the world’s defences against outbreaks of some of the world’s most dangerous pathogens, for the benefit of all,” explains **CEPI’s Executive Director of Research & Development Dr Kent Kester**. “If we solve the scientific challenge of developing all-in-one filovirus vaccines now, we can ensure the world is ready to respond at speed to newly emerging filoviruses and potentially take the threat of future filovirus pandemics off the table.”
The research will use cutting-edge artificial intelligence to design immunogens – the substance in a vaccine that provokes an immune response – that may be capable of protecting against more than one filovirus. These immunogens will be combined with a ferritin-based protein-nanoparticle vaccine platform to create a range of vaccine candidates that will be tested in preclinical studies to establish proof of concept. The most promising vaccine candidate will be advanced to the point where it is ready to rapidly enter Phase I clinical trials should an unknown filovirus outbreak emerge.
The ferritin nanoparticle vaccine platform is favourable for use in low- and middle-income countries as it does not require complex frozen storage that can impact access to doses in low-resource settings. It has previously been tested in Phase I clinical trials for influenza and COVID-19 vaccines, which generated positive safety data.
**Professor Peter S. Kim, the Virginia & D.K. Ludwig Professor of Biochemistry, at the Stanford School
... (truncated, 7 KB total)Resource ID:
69b355dcd30c8dd9 | Stable ID: NDkzODIxYj